医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medacta Japan Highlights Success of 2nd Japanese M.O.R.E. Symposium

2017年11月10日 AM08:00
このエントリーをはてなブックマークに追加


 

FUKUOKA, Japan

Medacta Japan, a subsidiary of Medacta International, the privately held, family-owned global leader in the design of innovative joint replacement and spine surgery products, today announced the success of its 2nd Japanese M.O.R.E Symposium, held on September 30 to October 1, 2017 and attended by over 300 medical professionals.

Reflecting Medacta’s ongoing commitment to continuous medical education, the event focused on how implant design, techniques and patient-specific treatment can improve outcomes and patient satisfaction in the changing orthopaedic landscape, positively impacting the sustainability of the healthcare system.

More than 40 Japanese orthopaedic surgery experts presented at the meeting, covering topics on innovation, education and healthcare sustainability, with important contributions from international experts who traveled from Australia, Europe and the United States to attend the event.

“Surgical education and training has been a pillar of Medacta’s mission and identity since the company began. We believe it is the foundation for optimal clinical outcomes and both patient and surgeon satisfaction,” said Francesco Siccardi, Executive Vice President of Medacta International. “The success and the incredible growth of Medacta Japan, in both joint and spine, is a further confirmation of that belief. We’re honored that a growing number of surgeons depend on us as a reliable partner, and we will do our best to maintain our vision for a bright future in Japan.”

For more information about the 2nd Japanese M.O.R.E. Symposium and Medacta, including scientific sessions, visit: https://2more-jpn.medacta.com/.

About Medacta International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171109006703/en/

CONTACT

For Medacta International, Inc.
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com

同じカテゴリーの記事 

  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究